Elevated level of the proinflammatory chemokine, RANTES/CCL5, in the periaqueductal grey causes hyperalgesia in rats

Eur J Pharmacol. 2008 Sep 11;592(1-3):93-5. doi: 10.1016/j.ejphar.2008.07.009. Epub 2008 Jul 11.

Abstract

The present data provide the first in vivo evidence that the proinflammatory chemokine, Regulated on Activation Normal T cell Expressed and Secreted (RANTES/CCL5) microinjected directly into the periaqueductal grey in rats, a brain region critical to the processing of pain signals, and a primary site of action of many analgesic compounds, induced hyperalgesia. Pretreatment with antibodies against RANTES/CCL5 prevented the hyperalgesic response, indicating that RANTES/CCL5 is able to interfere with the control of hyperalgesia at the level of the periaqueductal grey and suggesting that chemokine blockers could have analgesic properties.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antibodies, Blocking / pharmacology
  • Chemokine CCL5 / antagonists & inhibitors
  • Chemokine CCL5 / metabolism
  • Chemokine CCL5 / physiology*
  • Hyperalgesia / metabolism*
  • Male
  • Microinjections
  • Pain Measurement
  • Pain Threshold
  • Periaqueductal Gray / metabolism*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Antibodies, Blocking
  • Chemokine CCL5